Work

Tislelizumab, bevacizumab, and chemotherapy as second-line therapy in PD-L1-positive, RAS-mutant metastatic colorectal cancer: A single-arm, phase II clinical trial.

Year: 2026

Type: conference-abstract

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e15540

Authors: Luoyan Ai, Xiaojing Xu

Institutions: Fudan University, Fudan University Shanghai Cancer Center, Zhongshan Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162684769

Cites:

Cited by:

Related to: